Follow-up: Lyophilisation and why the cake looks the way it does

Lyophilisation and why the cake looks the way it does Writing it up because I had to work it out twice and would rather nobody else did.

I would like to understand what this number means before I repeat it anywhere.

A Janoshik report on a tirzepatide lot gives 97.1% purity. The supplier certificate for the same lot states 98.3%. Both documents name a reversed-phase method; neither states the same gradient.

My question is not "who is right". It is: given that those two figures were produced by different methods, what is the largest difference I should expect from method alone, and at what point does a gap stop being explainable that way?

Isotonicity: an isotonic solution has the same osmotic pressure as blood. Non-isotonic solutions can cause discomfort on injection. Injectable peptide solutions are formulated to be isotonic.

I read the opening post twice before replying, because I had assumed the opposite.

Excipients and their purposes: mannitol, sucrose, or other sugars in lyophilised formulations protect the peptide during drying and storage. They are not impurities; they are functional components.

This follows post #2 rather than contradicting it.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

On the opening post — agreed on the reasoning, with one qualification.

Container closure: the vial material, rubber closure, and sealing all affect permeability to water and oxygen. Glass is less permeable than plastic. Rubber quality matters.

Fill volume and headspace: the amount of solution in a vial and the air above it affect how much the solution is exposed to oxygen during storage. Less headspace means less oxygen exposure.

Picking up post #5: that is the part I would want checked first.

Emulsification and suspensions: some formulations are emulsions or suspensions rather than solutions. Semaglutide formulations are solutions; some other compounds are suspensions. The physical form affects stability and administration.

Buffers and pH: the pH of a solution is buffered to maintain stability. The buffer system (phosphate, Tris, or other) is chosen to keep the solution at the pH where the peptide is most stable.

post #9 is right about the mechanism and I think understates the practical bit.

Lyophilisation and reconstitution: the powder is stable for extended periods if kept cool and dry. Once reconstituted, stability decreases because the dissolved peptide is more vulnerable to oxidation and other degradation.

Antioxidants: compounds that prevent oxidation (which damages peptides) are sometimes included. Methionine oxidation is a common degradation pathway and antioxidants help prevent it.

On post #8 — agreed on the reasoning, with one qualification.

Amino acid residues and formulation: the specific sequence and composition of a peptide affects what formulation conditions it tolerates. Sequences high in methionine need more antioxidant protection. Sequences prone to aggregation need different pH or additive protection.

Antioxidants: compounds that prevent oxidation (which damages peptides) are sometimes included. Methionine oxidation is a common degradation pathway and antioxidants help prevent it.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.